Minimizing and managing treatment-associated complications in patients with chronic lymphocytic leukemia

References

• National Cancer Institute. Surveillance epidemiology and end results cancer statistics review. NCI. USA; 2016.
   Google Scholar
• Nabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical review. JAMA. 2014;312:2265–2276.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines. Blood. 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Kaur V, Swami A. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. Ann Hematol. 2017;96:1175–1184.
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287–6296.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.
   PubMed Web of Science ®Google Scholar
• Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126:2213–2219.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Furman RR, Coutre SE, et al. Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Blood. 2016;128:233.
   Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–2506.
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539–2549.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. Ibrutinib (PCI-32765) antagonizes rituximab-dependent NK-cell mediated cytotoxicity. Blood. 2013;122(21):373.
   Web of Science ®Google Scholar
• Borge M, Belen Almejun M, Podaza E, et al. Ibrutinib impairs the phagocytosis of rituximab coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. Haematologica. 2015;100(4):e140–142.
   PubMed Web of Science ®Google Scholar
• Yin Q, Sivina M, Robins H, et al. Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia. J Immunol. 2017;198(4):1740–1747.
   PubMed Web of Science ®Google Scholar
• Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133(12):1298–1307.
   PubMed Web of Science ®Google Scholar
• Rogers KA, Luay M, Zhao Q, et al. Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center. Blood. 2017;130(Suppl 1):830.
   Google Scholar
• Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131(17):1955–1959.
   PubMed Web of Science ®Google Scholar
• Woyach JA. Ibrutinib and Aspergillus a Btk-targeted risk. Blood. 2018;132(18):1869–1870.
   PubMed Web of Science ®Google Scholar
• Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833–843.e835.
   PubMed Web of Science ®Google Scholar
• de Zwart L, Snoeys J, De Jong J, et al. Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. Clin Pharmacol Ther. 2016;100(5):548–557.
   PubMed Web of Science ®Google Scholar
• Quek LS, Bolen J, Watson SP. A role for Bruton’s tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol. 1998;8(20):1137–1140.
   PubMed Web of Science ®Google Scholar
• Futatani T, Watanabe C, Baba Y, et al. Bruton’s tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females. Br J Haematol. 2001;114(1):141–149.
   PubMed Web of Science ®Google Scholar
• Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014 18;124(26):3991–3995.
   PubMed Web of Science ®Google Scholar
• Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015;29(4):783–787.
   PubMed Web of Science ®Google Scholar
• Lipsky AH, Farooqui MZ, Tian X, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015;100(12):1571–1578.
   PubMed Web of Science ®Google Scholar
• Barrientos JC 1, Burger JA 2, JC B, et al. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leuk Lymphoma. 2019;60(4):1000–1005.
   PubMed Web of Science ®Google Scholar
• Barr PM, Robak T, Owen C, et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018;103(9):1502–1510.
   PubMed Web of Science ®Google Scholar
• Brown JR, Moslehi J, Ewer MS, et al. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis. Br J Haematol. 2019;184(4):558–569.
   PubMed Web of Science ®Google Scholar
• Yun S, Vincelette ND, Acharya U, et al. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk. 2017;17(1):31–37 e13.
   PubMed Web of Science ®Google Scholar
• Pavlik A, Barr H, Dotson E, et al. Major bleeding complications among patients treated with ibrutinib and concomitant antiplatelet, anticoagulant, or supplemental therapy. Blood. 2016;128:4387.
   Web of Science ®Google Scholar
• Jones JA, Hillmen P, Coutre S, et al. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Br J Haematol. 2017;178(2):286–291.
   PubMed Web of Science ®Google Scholar
• Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–745.
   PubMed Web of Science ®Google Scholar
• Gifkins DM, Matcho A, Yang H, et al. Incidence of major hemorrhage among CLL and MCL patients compared to the general elderly population: an analysis of the US SEER-medicare linked database. Blood. 2015;126:3268.
   Web of Science ®Google Scholar
• Chanan-Khan A, Cramer P, Demirkan F, et al. Insights into the management of adverse events in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: experience from the phase 3 HELIOS study of ibrutinib combined with bendamustine/rituximab. Blood. 2015;126(23):2936.
   Web of Science ®Google Scholar
• Winqvist M, Asklid A, Andersson PO, et al. Real–world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. Haematologica. 2016;101(12):1573–1580.
   PubMed Web of Science ®Google Scholar
• Iskierka-Jażdżewska E, Hus M, Giannopoulos K, et al. Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG). Leuk Lymphoma. 2017;58(10):2485–2488.
   PubMed Web of Science ®Google Scholar
• Kunk PR, Mock J, Devitt ME, et al. Major bleeding with ibrutinib: more than expected. Blood. 2016;128:3229.
   Web of Science ®Google Scholar
• Anand S, Yusuf S, Xie C, et al. Warfarin antiplatelet vascular evaluation trial I. oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357(3):217–227.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Levy V, Tam CS, et al. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol. 2016;175(3):462–466.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;372(15):1430–1440.
   PubMed Web of Science ®Google Scholar
• Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15(10):1090–1099.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200–211.
   PubMed Web of Science ®Google Scholar
• Kapelios CJ, Bonou MS, Diamantopoulos P, et al. Ibrutinib-related atrial fibrillation: therapeutic challenges. J Oncol Pharm Pract. 2019;25(5):1258–1260.
   PubMed Web of Science ®Google Scholar
• de Weerdt I, Koopmans SM, Kater AP, et al. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica. 2017;102(10):1629–1639.
   PubMed Web of Science ®Google Scholar
• Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129(19):2612–2615.
   PubMed Web of Science ®Google Scholar
• Weidner AS, Panarelli NC, Geyer JT, et al. Idelalisib-associated colitis: histologic findings in 14 patients. Am J Surg Pathol. 2015;39(12):1661–1667.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–1018.
   PubMed Web of Science ®Google Scholar
• Louie CY, DiMaio MA, Matsukuma KE, et al. Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides. Am J Surg Pathol. 2015;39(12):1653–1660.
   PubMed Web of Science ®Google Scholar
• Forum UC. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016;101(12):1563–1572.
   PubMed Web of Science ®Google Scholar
• Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96(7):2455–2461.
   PubMed Web of Science ®Google Scholar
• Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128(1):138–140.
   PubMed Web of Science ®Google Scholar
• Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874–879.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Parikh SA, Noseworthy PA, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017;58(7):1630-1639.
   Google Scholar
• McMullen JR, Boey EJ, Ooi JY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124:3829–3830.
   PubMed Web of Science ®Google Scholar
• Pretorius L, Du XJ, Woodcock EA, et al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am J Pathol. 2009;175:998–1009.
   PubMed Web of Science ®Google Scholar
• McMullen JR, Amirahmadi F, Woodcock EA, et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci. 2007;104:612–617.
   PubMed Web of Science ®Google Scholar
• Al-Nawakil C, Goudot F, Ysebaert L, et al. Atrial fibrillation and ibrutinib: advocacy for guidelinesSupplement: abstracts from the XVI international workshop on chronic lymphocytic leukemia 2015 Sydney, Australia. Leuk Lymphoma. Abstract 160. 2015;56(S1):1-166.
   Google Scholar
• Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120–129.
   PubMed Web of Science ®Google Scholar
• Vrontikis A, Carey J, Gilreath JA, et al. Proposed algorithm for managing ibrutinib related atrial fibrillation. Oncology (Williston Park). 2016;30(11):970–974.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Katchman H, Polliack A. Severe hepatitis B virus reactivation related to ibrutinib monotherapy. Ann Hematol. 2017;96(4):689–690.
   PubMed Web of Science ®Google Scholar
• Molica S, Levato L, Mirabelli R. Chronic lymphocytic leukemia, autoimmune haemolytic anemia and ibrutinib: a case report and review of the literature. Leuk Lymphoma. 2016;57:735–737.
   PubMed Web of Science ®Google Scholar
• Iberri DJ, Kwong BY, Stevens LA, et al. Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. Br J Haematol. 2018;180(1):164–166.
   PubMed Web of Science ®Google Scholar
• Bitar C, Farooqui MZ, Valdez J, et al. Hair and nail changes during long-term therapy with ibrutinib for chronic lymphocytic leukemia. JAMA Dermatol. 2016;152(6):6987–7001.
   Web of Science ®Google Scholar
• Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2019 Oct 18. DOI:10.1038/s41375-019-0602-x
   Google Scholar
• Shustik C, Bence-Bruckler I, Delage R, et al. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. Ann Hematol. 2017;96(7):1185–1196.
   PubMed Web of Science ®Google Scholar
• Blunt MD, Steele AJ. Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia. Leuk Res Rep. 2015;4:60–63.
   PubMedGoogle Scholar
• Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. 5th European conference on infections in leukaemia (ECIL-5), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organisation for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN). J Antimicrob Chemother. 2016;71(9):2397–2404.
   PubMed Web of Science ®Google Scholar
• Khodavaisy S, Mortaz E, Mohammadi F, et al. Pneumocystis jirovecii colonization in Chronic Obstructive Pulmonary Disease (COPD). Curr Med Mycol. 2015;1(1):42–48.
   PubMedGoogle Scholar
• Cuneo A, Barosi G, Danesi R, et al. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper. Hematol Oncol. 2019;37(1):3–14.
   PubMed Web of Science ®Google Scholar
• Cooley L, Dendle C, Wolf J, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J. 2014;44(12b):1350–1363.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization; 2015.
   Google Scholar
• S BJ C, Brown JR, de Vos S, et al. Safety of idelalisib in B cell malignancies: integrated analysis of eight clinical trials. J Clin Oncol. 2015; 33(supp); abstr e18030.
   Google Scholar
• Coutre SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56(10):2779–2786.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood. 2015;126(25):2686–2694.
   PubMed Web of Science ®Google Scholar
• WG CS W, Flinn I, Gopal AK, et al. Management of transaminase elevations in patients receiving idelalisib. J Clin Oncol. 2016;34:1532.
   Web of Science ®Google Scholar
• Kreiniz N, Beyar Katz O, Polliack A, et al. The clinical spectrum of hepatic manifestations in chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2017;17(12):863–869.
   PubMed Web of Science ®Google Scholar
• Prescribing information: ZYDELIG (idelalisib) tablets, for oral use. 2016 [cited 2016 Sep 3]. Available from: http://www.gilead.com/~/media/Files/pdfs/medicines/oncology/zydelig/zydelig_pi.pdf
   Google Scholar
• Jin F, Robeson M, Zhou H, et al. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment. J Clin Pharmacol. 2015;55(8):944–952.
   PubMed Web of Science ®Google Scholar
• Jung M, Rice L. Unusual autoimmune nonhematologic complications in chronic lymphocytic leukemia. Cl Lymph Myelo Leuk. 2011;11:S10–S13.
   PubMedGoogle Scholar
• D’Arena G, Guariglia R, La Rocca F, et al. Autoimmune cytopenias in chronic lymphocytic leukemia. Clin Dev Immunol. 2013;730131:2013.
   Google Scholar
• Ferrell LD, Kakar S. Liver pathology: demos Medical Publishing; Chapter 3: autoimmune hepatitis/Overlap syndromes. Case 3.5.Syncytial Giant Cell Hepatitis. Demos Medical. 36–37; 2011.
   Google Scholar
• Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123(22):3406–3413.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014;123(22):3398–3405.
   PubMed Web of Science ®Google Scholar
• Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390–3397.
   PubMed Web of Science ®Google Scholar
• Haustraete E, Obert J, Diab S, et al. Idelalisib-related pneumonitis. Eur Respir J. 2016;47(4):1280–1283.
   PubMed Web of Science ®Google Scholar
• Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of Pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017;152(2):271–281.
   PubMed Web of Science ®Google Scholar
• Gupta NK, Andreadis C. New meets old: a case study and review of novel therapeutics for the treatment of CLL in older patients. J Natl Compr Canc Netw. 2014;12(10):1371–1375.
   PubMed Web of Science ®Google Scholar
• Mayer AP, Files JA, Biria N. There is a fungus … among us. J Womens Health (Larchmt). 2012;21(7):798–799.
   PubMed Web of Science ®Google Scholar
• Romagnoli M 1, Bigliazzi C, Casoni G, et al. The role of transbronchial lung biopsy for the diagnosis of diffuse drug-induced lung disease: a case series of 44 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25(1):36–45.
   PubMed Web of Science ®Google Scholar
• DesPrez K, McNeil JB, Wang C, et al. Oxygenation saturation index predicts clinical outcomes in ARDS. Chest. 2017;152(6):1151–1158.
   PubMed Web of Science ®Google Scholar
• Bonniaud P, Georges M, Favrolt N, et al. Drug-induced interstitial lung diseases. Rev Prat. 2014;64(7):951–956.
   PubMedGoogle Scholar
• Gentile M, Petrungaro A, Uccello G, et al. Venetoclax for the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017;26:1307–1316.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Stilgenbauer S, Seymour JF, et al. Venetoclax in patients with previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2017;23:4527–4533.
   PubMed Web of Science ®Google Scholar
• Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127:3215–3224.
   PubMed Web of Science ®Google Scholar
• Coutre S, Choi M, Furman RR, et al. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018;131:1704–1711.
   PubMed Web of Science ®Google Scholar
• Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19:65–75.
   PubMed Web of Science ®Google Scholar
• Tosi P, Barosi G, Lazzaro C, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica. 2008;93:1877–1885.
   PubMed Web of Science ®Google Scholar
• McBride A, Westervelt P. Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies. J Hematol Oncol. 2012;5:75.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice. Guidelines in oncology: non-Hodgkin’s lymphomas, version 4. Fort Washington, PA: National Comprehensive Cancer Network,Inc.; 2014.
   Google Scholar
• Hochberg J, Cairo MS. Tumor lysis syndrome: current perspective. Haematologica. 2008;93:9–13.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2009;7:263–271.
   PubMedGoogle Scholar
• Samo J. Prevention and management of tumor lysis syndrome in adults with malignancy. J Adv Pract Oncol. 2013;4:101–106.
   PubMedGoogle Scholar
• Cartron G, de Guibert S, Dilhuydy MS, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014;124:2196–2202.
   PubMed Web of Science ®Google Scholar
• Jensen M, Winkler U, Manzke O, et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol. 1998;77:89–91.
   PubMed Web of Science ®Google Scholar
• Herman SE, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia. 2014;28:2188–2196.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Heitner Enschede S, Cerri E, et al. Tumor lysis syndrome in chronic lymphocytic leukemia with novel targeted agents. Oncologist. 2017;22(11):1283–1291.
   PubMed Web of Science ®Google Scholar
• Wilson FP, Berns JS. Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis. 2014;21:18–26.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26:2767–2778.
   PubMed Web of Science ®Google Scholar
• Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364:1844–1854.
   PubMed Web of Science ®Google Scholar
• Venclexta (venetoclax) [package insert]. North Chicago, IL: AbbVie Inc. (2016).
   Google Scholar
• Mirrakhimov AE, Voore P, Khan M, et al. Tumor lysis syndrome: a clinical review. World J Crit Care Med. 2015;4:130–138.
   PubMedGoogle Scholar
• Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3–11.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Frame JN, Vena D, et al. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol. 1998;16:2313–2320.
   PubMed Web of Science ®Google Scholar
• Spina M, Nagy Z, Ribera JM, et al. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015;26:2155–2161.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Fayad LE, Fanale MA, et al. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012;23:1640–1645.
   PubMed Web of Science ®Google Scholar
• Robak P, Robak T. Novel synthetic drugs currently in clinical development for chronic lymphocytic leukaemia. Expert Opin Investig Drugs. 2017;26:1249–1265.
   PubMed Web of Science ®Google Scholar
• Mato AR, Hill BT, Lamanna N, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukaemia: results from a multicenter study of 683 patients. Ann Oncol. 2017;28:1050–1056.
   PubMed Web of Science ®Google Scholar
• Walter HS, Rule SA, Dyer MJ, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127(04):411–419.
   PubMedGoogle Scholar
• Wu J, Liu C, Tsui ST, et al. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016;9(1):80.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukaemia. N Engl J Med. 2016;374(4):323–332.
   PubMed Web of Science ®Google Scholar
• Walter HS, Jayne S, Rule SA, et al. Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059. Blood. 2017;129(20):2808–2810.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second generation BTK inhibitor. J Hematol Oncol. 2016;9(1):21.
   PubMedGoogle Scholar
• Denzinger V, Busygina K, Jamasbi, et al. Optimizing platelet GPVI inhibition versus haemostatic impairment by the Btk inhibitors ibrutinib, acalabrutinib, ONO/GS-4059, BGB-3111 and evobrutinib. Thromb Haemost. 2019;119(3):397–406.
   PubMed Web of Science ®Google Scholar
• Chellappa S, Kushekhar K, Munthe LA, et al. The PI3K p110δ isoform inhibitor idelalisib preferentially inhibits human regulatory T cell function. J Immunol. 2019;202(5):1397–1405.
   PubMed Web of Science ®Google Scholar
• Gilead Sciences Inc., written communication. United States Securities and Exchange Comission. Foster City California, USA. 2016 Mar 11.
   Google Scholar
• Patel K, Pagel JM. Exploring a future for PI3K inhibitors in chronic lymphocytic leukaemia. Curr Hematol Malig Rep. 2019;14(4):292–301.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Patel M, Kahl BS, et al. Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamicactivity in chronic lymphocytic leukaemia and small lymphocytic lymphoma in aphase 1 study. Am J Hematol. 2018;93:1318–1326.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Brien S, Kahl B, et al. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood. 2018 22;131(8):877–887.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132:2446–2455.
   PubMed Web of Science ®Google Scholar
• Rodrigues DA, Sagrillo FS, Fraga CAM. Duvelisib: a 2018 novel fda-approved small molecule inhibiting phosphoinositide 3-kinases. Pharmaceuticals (Basel). 2019;12(2):E69.
   PubMedGoogle Scholar
• Burris HA 3rd, Flinn IW, Patel MR, et al. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018;19(4):486–496.
   PubMed Web of Science ®Google Scholar
• Mato AR, Roeker LE, Eyre TA, et al. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Blood Adv. 2019;3(10):1568–1573.
   PubMed Web of Science ®Google Scholar